Christopher M. Counter

The Counter lab studies the molecular mechanisms that underly to the onset of human cancers, with the goal to prevent cancer initiation or progression.  The lab uses ultra-senstitive sequencing platforms and proteomic-coupled CRISPR/Cas9 screens to elucidate the factors that mold the mutational patterns selected to initiate the process of tumorigenesis.  See https://counter.labs.duke.edu/ for further details.